Table 4. Daptomycin exposure and development of resistance during therapy in patients with isogenic pairs of ST736 strains.
| Year | Patient | ST736 isolate | Source | Interval between isolation (days) | Prior daptomycin exposure | Daptomycin MIC (μg/mL) | liaFSR mutation(s) | cls mutation(s) |
|---|---|---|---|---|---|---|---|---|
| 2010 | 107 | E51 | Blood | - | 4 | liaR.W73C, liaS.T120A | - | |
| E53 | Wound | 36 | + | 64 | liaR.W73C, liaS.T120A | N13I | ||
| 2011 | 74 | E148 | Blood | + | 2 | liaR.W73C, liaS.T120A | ||
| E91 | Blood | 9 | + | 64 | liaR.W73C, liaS.T120A | N13I | ||
| 124 | E145 | Blood | + | 2 | liaR.W73C, liaS.T120A | |||
| E146 | Urine | 26 | + | 32 | liaR.W73C, liaS.T120A | N13I | ||
| 2013 | 161 | E232 | Pelvic | - | 4 | liaR.W73C, liaS.T120A | ||
| E243 | Peritoneal fluid | 44 | + | >256 | liaR.W73C, liaS.T120A | |||
| 184 | E352 | Wound | - | 2 | liaR.W73C, liaS.T120A | |||
| E242 | Wound | 4 | + | 8 | liaR.W73C, liaS.T120A | |||
| 185 | E300 | Wound | - | 3 | liaR.W73C, liaS.T120A | |||
| E253 | Wound | 47 | + | >256 | liaR.W73C, liaS.T120A | A20D |